Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Migraine

Telcagepant provides new hope for people with migraine

The triptan drugs provide effective migraine relief for many people. Nevertheless, a substantial number of migraine-affected individuals are unresponsive to triptans, and such therapy can also lead to an array of adverse effects. A new class of antimigraine drugs, currently undergoing clinical trials, could offer hope to those for whom triptan medication is unsuitable.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Ferrari, M. D., Roon, K. I., Lipton, R. B. & Goadsby, P. J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668–1675 (2001).

    CAS  Article  Google Scholar 

  2. Edvinsson, L. et al. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin. Sci. (Lond.) 109, 335–342 (2005).

    CAS  Article  Google Scholar 

  3. Ho, T. W. et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372, 2115–2123 (2008).

    CAS  Article  Google Scholar 

  4. McCulloch, J., Uddman, R., Kingman, T. A. & Edvinsson, L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc. Natl Acad. Sci. USA 83, 5731–5735 (1986).

    CAS  Article  Google Scholar 

  5. Liu, Y., Broman, J. & Edvinsson, L. Central projections of the sensory innervation of the rat middle meningeal artery. Brain Res. 1208, 103–110 (2008).

    CAS  Article  Google Scholar 

  6. Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).

    CAS  Article  Google Scholar 

  7. Olesen, J. et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104–1110 (2004).

    CAS  Article  Google Scholar 

  8. Ho, T. W. et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70, 1304–1312 (2008).

    CAS  Article  Google Scholar 

  9. Edvinsson, L. et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol. 434, 49–53 (2002).

    CAS  Article  Google Scholar 

  10. Regan, C. P., Stump, G. L., Kane, S. A. & Lynch, J. J. Jr Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J. Pharmacol. Exp. Ther. 328, 571–578 (2009).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lars Edvinsson.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Edvinsson, L. Telcagepant provides new hope for people with migraine. Nat Rev Neurol 5, 240–242 (2009). https://doi.org/10.1038/nrneurol.2009.49

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.49

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing